EIC Accelerator

Hummink is a company specializing in additive manufacturing technology, focusing on nano-printing solutions that enable precise design and manufacturing at the nanoscale. Founded in 2020 in Paris by Amin M'barki, Pascal Boncenne, Lydéric Bocquet, Alessandro Siria, and Antoine Nigues, Hummink utilizes a patented technology that integrates a nanometric pen with an oscillating microresonator. This innovative approach allows for the capillary deposition of various liquids, equipping clients in the semiconductor and molecular diagnostic industries with the capability to create large objects while maintaining exceptional resolution and precision on substrates ranging from millimetric to centimetric scales.

Hummink is a company specializing in additive manufacturing technology, focusing on nano-printing solutions that enable precise design and manufacturing at the nanoscale. Founded in 2020 in Paris by Amin M'barki, Pascal Boncenne, Lydéric Bocquet, Alessandro Siria, and Antoine Nigues, Hummink utilizes a patented technology that integrates a nanometric pen with an oscillating microresonator. This innovative approach allows for the capillary deposition of various liquids, equipping clients in the semiconductor and molecular diagnostic industries with the capability to create large objects while maintaining exceptional resolution and precision on substrates ranging from millimetric to centimetric scales.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.